PTC Therapeutics, Inc. $PTCT Shares Sold by State of Alaska Department of Revenue

Posted by Francis Steltz on Oct 21st, 2026

State of Alaska Department of Revenue lessened its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 43.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,065 shares of the biopharmaceutical company’s stock after selling 13,717 shares during the quarter. State of Alaska Department of Revenue’s holdings in PTC Therapeutics were worth $1,169,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new position in shares of PTC Therapeutics during the 2nd quarter worth $67,000. EverSource Wealth Advisors LLC raised its holdings in shares of PTC Therapeutics by 16.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 151 shares in the last quarter. Harbor Investment Advisory LLC bought a new position in shares of PTC Therapeutics during the 2nd quarter valued at $81,000. Quantbot Technologies LP bought a new position in shares of PTC Therapeutics during the 2nd quarter valued at $112,000. Finally, GAMMA Investing LLC lifted its stake in shares of PTC Therapeutics by 58.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 534 shares during the last quarter.

PTC Therapeutics Price Performance

NASDAQ:PTCT opened at $62.92 on Wednesday. PTC Therapeutics, Inc. has a 12 month low of $58.80 and a 12 month high of $90.87. The company’s 50 day moving average is $66.93 and its 200-day moving average is $71.68.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.68. The firm had revenue of $360.52 million during the quarter, compared to analyst estimates of $298.63 million. PTC Therapeutics’s quarterly revenue was up 101.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.83) earnings per share. Sell-side analysts forecast that PTC Therapeutics, Inc. will post 1.19 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Morgan Stanley upped their price objective on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. UBS Group restated a “buy” rating and set a $90.00 target price (up from $80.00) on shares of PTC Therapeutics in a report on Thursday, October 15th. Raymond James Financial set a $106.00 price target on PTC Therapeutics in a research report on Tuesday. Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, Cantor Fitzgerald upped their price target on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.93.

Check Out Our Latest Stock Report on PTCT

Insider Activity

In other PTC Therapeutics news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the completion of the sale, the director directly owned 22,500 shares in the company, valued at $1,466,100. This represents a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 12,500 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $72.94, for a total transaction of $911,750.00. Following the sale, the director owned 1,349,094 shares of the company’s stock, valued at $98,402,916.36. This trade represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,370 shares of company stock worth $5,322,261. Insiders own 5.30% of the company’s stock.

About PTC Therapeutics

(Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.